
|Videos|November 15, 2021
With Oral Agents Common, Oncology Pharmacists Are Essential in Treatment of Multiple Myeloma
With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members.
Advertisement
With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members, according to Terri L. Parker, MD, assistant medical director of Smilow Cancer Hospital Care Center at Yale New Haven Health.
In an interview, Parker discussed key considerations for treatment selection, safety data on the drug selinexor, the importance of facilitating collaboration between experts, and upcoming clinical trials and research that she is keeping an eye on.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
5








































































































































